# 2025-11794: FDA Creates a New Regulatory Category for a Brain-Infection Test

2025-11794, Medical Devices; Immunology and Microbiology Devices; Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11794
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11794
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27234
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Creates a New Regulatory Category for a Brain-Infection Test

## Summary

The FDA is officially putting the herpes simplex virus test for brain infections into a safer, easier-to-manage category called Class II. This change means the test will have special rules to keep it safe and effective, helping patients get quicker access to this important tool without unnecessary red tape. The new classification is effective June 26, 2025, and could save time and money for makers and users of the test.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the herpes simplex virus nucleic acid-based assay for central nervous system infections into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the herpes simplex virus nucleic acid-based assay for central nervous system infections. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- HSV CNS Test Reclassified to Class II: benefit, medium. If you make or sponsor this herpes simplex virus (HSV) nucleic acid test for central nervous system (CNS) infections, the FDA has classified it as Class II (special controls). This order is effective June 26, 2025, the device is subject to premarket notification under section 510(k), and the classi…
- Developers Must Meet Detailed Special Controls: cost, high. If you develop this HSV CNS assay, you must provide detailed design verification and validation documentation, including device description (components, ancillary reagents, primer design), analytical performance data (limit of detection, reactivity, inclusivity, precision, reproducibility, interfer…
- Labeling Must Explain Results and Warn on Negatives: benefit, low. If you use this HSV CNS test, the labeling must give a detailed explanation of how to interpret results and the acceptance criteria, and it must state that negative results do not preclude HSV-1 or HSV-2 infection and should not be used as the sole basis for treatment or other patient management de…
- De Novo Classification Enables Future 510(k) Predicates: benefit, medium. Because FDA used the De Novo process to classify this device into Class II, this device can serve as a predicate for future similar devices, allowing other sponsors to use the less burdensome 510(k) pathway instead of submitting a De Novo request or premarket approval application.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11794 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11794/medical-devices-immunology-and-microbiology-devices-classification-of-the-herpes-simplex-virus)
- [2025-11794 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11794.pdf)

## Related
- [Previous: 2025-11793, Medical Devices; Hematology and Pathology Devices; Classification of the Fluore…](https://policyrisk.com/federal-register/2025-11793)
- [Next: 2025-11796, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classifica…](https://policyrisk.com/federal-register/2025-11796)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11794 (as of 2026-11-05).
